Your Ad Here

Genomic Test Helps Personalized Treatment in Breast Cancer Patients

 

Breast cancer is a heterogeneous disease that affects each woman differently and makes it respond differently to the therapy they received. This situation has led to investigate science personalized treatments to optimize results and reduce adverse events such as hair loss, high risk of infection, diarrhea, loss of appetite and malaise.

A breakthrough in the test genomic medicine 'Oncotype DX', which examines 21 genes of the tumor in patients with breast cancer stages I and II, enabling oncologists, surgeons and pathologists to determine the best treatment for the patient and the likelihood of a recurrence of their breast cancer ten years.

Effective treatment

Breast cancer has different factors that are evaluated by specialists in each case to decide their treatment such as: patient age, tumor size, histological grade, if a woman is premenopausal or postmenopausal, the clinical stage of disease – early or late, and if there is metastasis, among others.

With 'Oncotype DX' doctors can also learn about the aggressiveness of the tumor in the early stages of the disease. This tool allows them to determine a prescription for stronger treatments such as chemotherapy or alone can be treated with hormone therapy, thereby reducing adverse events.

Thus, says Dr. Cortes, achieves several benefits to the patient as having a personalized, cost reduction, improved quality of life and a better survival. For health care benefits are in savings from reduced use of resources and materials for medical healing and win the battle against breast cancer.

About 'Oncotype DX'

It is the first genomic diagnostic test for type of breast cancer. In the United States has existed since 2004 for breast cancer patients with receptor-positive, node-negative and positive, representing more than 50 percent of all cases diagnosed each year and is the only accepted by the U.S. NCCN and ASCO guidelines.

In the U.S., one of the advantages of 'Oncotype DX' is that a large percentage of cases are reimbursed at public and private sectors.

 

0 comments:

Post a Comment

Hey Guys...
Type your message here...